Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. Martha Q. Lacy, MD
|
|
Give Review
Doctor Martha Q. Lacy, MD works in the field of Hematology. She graduated from University of Colorado Denver School of Medicine. University of Colorado Denver School of Medicine is a top medical university. University of Colorado Denver School of Medicine is ranked 35 in research and 8 in primary care medicine Doctor Martha Q. Lacy, MD is also a published doctor. She has 99 paper published. The most recent paper is: The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Publications
- The prognostic significance of CD45 expression by clonal bone marrow plasma Cells in patients with newly diagnosed multiple myeloma.
- Outcomes of primary refractory multiple Myeloma and the impact of novel therapies.
- Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem Cell transplantation.
- Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple Myeloma.
- Treatment outcomes, healthcare resource utilization, and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myel...
- Soluble suppression of tumorigenicity 2 (sST2), but not Galactin-3, adds to prognostication in patients with Systemic AL amyloidosis independent of NT-proBNP and Tropo...
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
- Clinical Course and Prognosis of Non-Secretory Multiple Myeloma.
- Multiple Myeloma after kidney transplantation.
- Quantification of clonal circulating plasma Cells in relapsed multiple myeloma.
- Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma Cell dyscrasias.
- Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma Cell dyscrasia coexist.
- Long-term outcome of patients with multiple Myeloma-related advanced renal failure following auto-SCT.
- Trends in survival of patients with primary plasma cell Leukemia: a population based analysis.
- Identification of cereblon binding proteins and relationship with response and survival following pomalidomide and dexamethasone in multiple Myeloma.
- Quantification of clonal circulating plasma Cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.
- High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
- Long-term Disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem Cell transplant.
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple Myeloma: a randomized phase 2 study.
- Phase 2 trial of intravenously administered plerixafor for stem Cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
- Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification.
- Long term response to lenalidomide in patients with newly diagnosed multiple Myeloma.
- Pomalidomide: New immunomodulatory agent with potent antiproliferative effects.
- Continued improvement in survival in multiple Myeloma: changes in early mortality and outcomes in older patients.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- The clinical significance of cereblon expression in multiple Myeloma.
- Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict EnGraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cel...
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- Implications of continued response after autologous stem Cell transplantation for multiple myeloma.
- A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
- Outcomes of patients with POEMS syndrome treated initially with radiation.
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple Myeloma.
- Patients with immunoglobulin light chain amyloidosis undergoing autologous stem Cell transplantation have superior outcomes compared with patients with multiple myelom...
- Refinement in patient selection to reduce treatment-related mortality from autologous stem Cell transplantation in amyloidosis.
- Salvage autologous stem Cell transplant is an effective regimen for relapsed multiple myeloma.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- Second auto-SCT for treatment of relapsed multiple Myeloma.
- Systemic amyloidosis associated with chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem Cell mobilization.
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple Myeloma.
- A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem Cell transplantation (ASCT) in patients with multiple myelo...
- Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases.
- Trends and outcomes of modern staging of solitary plasmacytoma of bone.
- Ten-year survival after autologous stem Cell transplantation for immunoglobulin light chain amyloidosis.
- Clinicopathologic correlations in multiple Myeloma: a case series of 190 patients with kidney biopsies.
- Trisomies in multiple Myeloma: impact on survival in patients with high-risk cytogenetics.
- High-dose melphalan and peripheral blood stem Cell transplantation for light-chain amyloidosis with cardiac involvement.
- Immunoglobulin D amyloidosis: a distinct entity.
- Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
- Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.
- Hematopoietic recovery kinetics predicts for poor CD34+ Cell mobilization after cyclophosphamide chemotherapy in multiple myeloma.
- The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.
- Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple Myeloma.
- Acute lung toxicity related to pomalidomide.
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory Disease.
- Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple Myeloma.
- New immunomodulatory drugs in Myeloma.
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple Myeloma: Results from a phase 2 trial.
- Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in Primary amyloidosis.
- Recent improvements in survival in primary Systemic amyloidosis and the importance of an early mortality risk score.
- Serum immunoglobulin free light-chain measurement in Primary amyloidosis: prognostic value and correlations with clinical features.
- Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune mo...
- Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) Myeloma.
- Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed Myeloma.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- Arterial Thrombosis complicates myeloma?
- Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple Myeloma in the era of novel therapie.
- Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into Disease biology in patients with POEMS syndrome.
- Pitfalls in the diagnosis of Primary amyloidosis.
- A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem Cell conditioning regimen in patients with multiple myeloma.
- Stem Cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.
- Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple Myeloma.
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple Myeloma: a comparative analysis of 411 patients.
- Pomalidomide: a new IMiD with remarkable activity in both multiple Myeloma and myelofibrosis.
- Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple Myeloma.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
- Idiotype-pulsed antigen-presenting Cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.
- Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple Myeloma.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
- Induction of a Chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the...
- Autologous stem Cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisc...
- Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem Cell transplantation.
- Autologous stem Cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
- Autologous stem Cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
- Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple Myeloma.
- Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with Systemic amyloidosis and no evidence of cardiac involvement by s...
- Serum uric acid: novel prognostic factor in primary Systemic amyloidosis.
- Improved survival in multiple Myeloma and the impact of novel therapies.
- Relationship between depth of response and outcome in multiple Myeloma.
- Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple Myeloma.
- Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed Myeloma.
- Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem Cell transplantation.
- Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary Systemic amyloidosis.
- Transplantation for amyloidosis.
- Treatment of newly diagnosed multiple Myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
- The activity of lenalidomide with or without dexamethasone in patients with primary Systemic amyloidosis.
Schools
University Of Colorado School Of Medicine
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Mayo School of Graduate Medical Education -
University of Colorado Denver School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1881668366 | |
| NPPES Provider LastName | LACY | |
| NPPES Provider FirstName | MARTHA | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1070.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 54.0 | |
| Percent Opioid Claims | 5.05 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881668366 |
| Last Name Of The Provider | LACY |
| First Name Of The Provider | MARTHA |
| View All |
Similar Doctors
|
|
Dr. Yolanda I. Garces, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn S. Harman, MD |
|
|
Dr. John C. Wiltsie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Cook, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Moynihan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian D. Koh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jann N. Sarkaria, MD
This Doctor is OpenDoctor Recommended.
|